Nerlynx — Medical Mutual
Breast Cancer, Recurrent or Metastatic Disease
Initial criteria
- Patient has HER2-positive disease
- Patient has progressed on 2 or more prior regimens
- Nerlynx will be used in combination with capecitabine
- Antidiarrheal prophylaxis will be initiated with the first dose of Nerlynx and provider will adjust the dose as necessary to manage the adverse effect
Reauthorization criteria
- Extended approval is 1 year for approvable indications
Approval duration
1 year